Estrella Immunopharma (NASDAQ:ESLA) Price Target Lowered to $8.00 at D. Boral Capital

Estrella Immunopharma (NASDAQ:ESLA) had its price target decreased by D. Boral Capital from $16.00 to $8.00 in a report released on Wednesday,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut Estrella Immunopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Estrella Immunopharma currently has an average rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Performance

Shares of Estrella Immunopharma stock opened at $1.06 on Wednesday. Estrella Immunopharma has a 1 year low of $0.73 and a 1 year high of $3.15. The firm’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.42. The firm has a market cap of $40.04 million, a PE ratio of -3.12 and a beta of 0.55.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.